94% of researchers rate our articles as excellent or good
Learn more about the work of our research integrity team to safeguard the quality of each article we publish.
Find out more
Gema Frühbeck1,2,3,4*
Javier Gómez-Ambrosi1,2,3Beatriz Ramírez1,2,3Amaia Mentxaka1,2
Amaia Rodríguez1,2,3
Sara Becerril1,2,3
Gabriel Reina5Victor Valentí6Rafael Moncada7Camilo Silva4
Victoria Catalán1,2,3*- 1Metabolic Research Laboratory, Clínica Universidad de Navarra, Pamplona, Spain
- 2CIBER Fisiopatología de la Obesidad y Nutrición (CIBEROBN), Instituto de Salud Carlos III, Pamplona, Spain
- 3Obesity and Adipobiology Group, Instituto de Investigación Sanitaria de Navarra (IdiSNA), Pamplona, Spain
- 4Department of Endocrinology and Nutrition, Clínica Universidad de Navarra, Pamplona, Spain
- 5Department of Microbiology, Clínica Universidad de Navarra, Pamplona, Spain
- 6Department of Surgery, Clínica Universidad de Navarra, Pamplona, Spain
- 7Department of Anesthesia, Clínica Universidad de Navarra, Pamplona, Spain
by Frühbeck G, Gómez-Ambrosi J, Ramírez B, Mentxaka A, Rodríguez A, Becerril S, Reina G, Valentí V, Moncada R, Silva C and Catalán V (2022) Front. Immunol. 13:832185. doi: 10.3389/fimmu.2022.832185
In the published article, there was an error in the Funding statement. Instead of “Instituto de Salud Carlos III”, the correct name for the funder is “Spanish Instituto de Salud Carlos III–Subdirección General de Evaluación y Fomento de la investigación–FEDER”. The correct Funding statement appears below.
Funding
Funded by Spanish Instituto de Salud Carlos III–Subdirección General de Evaluación y Fomento de la investigación–FEDER (project PI19/00785, PI20/00080 and PI20/00927) and CIBEROBN. Funding sources had no role in manuscript writing or the decision to submit it for publication.
The authors apologize for this error and state that this does not change the scientific conclusions of the article in any way. The original article has been updated.
Conflict of interest
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Publisher’s note
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.
Keywords: IL-36, inflammation, obesity, adipose tissue, macrophages, fibrosis
Citation: Frühbeck G, Gómez-Ambrosi J, Ramírez B, Mentxaka A, Rodríguez A, Becerril S, Reina G, Valentí V, Moncada R, Silva C and Catalán V (2023) Corrigendum: Increased levels of interleukin-36 in obesity and type 2 diabetes fuels adipose tissue inflammation by inducing its own expression and release by adipocytes and macrophages. Front. Immunol. 14:1138316. doi: 10.3389/fimmu.2023.1138316
Received: 05 January 2023; Accepted: 06 January 2023;
Published: 16 January 2023.
Approved by:
Frontiers Editorial Office, Frontiers Media SA, SwitzerlandCopyright © 2023 Frühbeck, Gómez-Ambrosi, Ramírez, Mentxaka, Rodríguez, Becerril, Reina, Valentí, Moncada, Silva and Catalán. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
*Correspondence: Victoria Catalán, dmNhdGFsYW5AdW5hdi5lcw==; Gema Frühbeck, Z2ZydWhiZWNrQHVuYXYuZXM=